


Edited by Andrew B. Hughes

 WILEY-VCH

Amino Acids, Peptides and Proteins in Organic Chemistry

Volume 4

Protection Reactions, Medicinal Chemistry,
Combinatorial Synthesis



Edited by
Andrew B. Hughes

Amino Acids, Peptides and Proteins in Organic Chemistry

Volume 4 - Protection Reactions, Medicinal Chemistry,
Combinatorial Synthesis



WILEY-VCH Verlag GmbH & Co. KGaA

The Editor

Andrew B. Hughes
La Trobe University
Department of Chemistry
Victoria 3086
Australia

All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2011 WILEY-VCH Verlag & Co. KGaA,
Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Composition Thomson Digital, Noida, India

Printing and Bookbinding Strauss GmbH,
Mörtenbach

Cover Design Schulz Grafik Design, Fußgönheim

Printed in the Federal Republic of Germany

Printed on acid-free paper

ISBN: 978-3-527-32103-2

Contents

List of Contributors XVII

1	Protection Reactions	1
	<i>Vommina V. Sureshbabu and Narasimhamurthy Narendra</i>	
1.1	General Considerations	1
1.2	α -Amino Protection (N^α Protection)	4
1.2.1	Non-Urethanes	4
1.2.1.1	Acyl Type	4
1.2.1.1.1	Monoacyl Groups	5
1.2.1.1.2	Groups Cleavable via Lactam Formation	6
1.2.1.1.3	Diacyl Groups	7
1.2.1.2	Phosphine-Type Groups	10
1.2.1.3	Sulfonyl-Type Groups	10
1.2.1.4	Alkyl-Type Groups	11
1.2.1.4.1	Triphenylmethyl (Trityl or Trt) Group	11
1.2.1.4.2	Benzhydryl Groups	12
1.2.1.4.3	<i>N,N</i> -Bis-Benzyl Protection	12
1.2.1.4.4	Vinyl Groups	12
1.2.1.5	Sulfanyl-Type Groups	13
1.2.2	Urethanes (Carbamates or Alkyloxycarbonyl Groups)	14
1.2.2.1	Formation of the Urethane Bond	16
1.2.2.2	Urethanes Derived from Primary Alcohols	16
1.2.2.2.1	Benzyloxycarbonyl (Cbz or Z) Group	16
1.2.2.2.2	Urethanes Cleaved by β -Elimination	19
1.2.2.2.3	Urethanes Cleaved via Michael-Type Addition	24
1.2.2.2.4	Allyloxycarbonyl (Aloc) Group	25
1.2.2.3	Urethane Groups Derived from Secondary Alcohols	25
1.2.2.4	Urethanes Derived from Tertiary Alcohols	25
1.2.2.4.1	<i>tert</i> -Butoxycarbonyl (Boc) Group	25
1.2.2.4.2	Boc Analogs	28
1.2.2.5	Other Aspects of Urethane Protectors	29

- 1.2.2.5.1 Formation of Dipeptide Impurities during the Introduction of Urethanes and Protocols to Overcome It 29
- 1.2.2.5.2 Introduction of Urethanes via Transprotection 30
- 1.2.2.5.3 Protection of the Nitrogen of α -Amino Acid *N*-Carboxy Anhydrides (NCAs) 31
- 1.2.2.5.4 *N* ^{α} -*N* ^{α} -bis-Protected Amino Acids 32
- 1.2.3 Other *N* ^{α} -Protecting Groups 32
- 1.2.3.1 α -Azido Acids as α -Amino Acid Precursors 33
- 1.2.3.2 One-Pot *N* ^{α} Protection and C ^{α} Activation 33
- 1.2.3.3 Effect of *N* ^{α} -Protecting Groups in the Synthesis of NMAs 33
- 1.3 Carboxy Protection 34
- 1.3.1 Methyl and Ethyl Esters 35
- 1.3.1.1 Substituted Methyl and Ethyl Esters 36
- 1.3.2 Benzyl Ester 36
- 1.3.2.1 Cleavage 36
- 1.3.3 Substituted Benzyl Esters 38
- 1.3.4 *tert*-Butyl Ester 38
- 1.3.5 Other Acid-Labile Esters 39
- 1.3.6 Temporary α -Carboxy Protection 39
- 1.3.7 α -Carboxy Protectors as Precursors to Useful Amino Acid Derivatives: Formation of Acid Hydrazides 41
- 1.4 Side-Chain Protection 41
- 1.4.1 ω -Amino Group of Diamino Acids 41
- 1.4.2 Guanidino Group of Arg 43
- 1.4.2.1 Protection Through Protonation 43
- 1.4.2.2 Nitration 44
- 1.4.2.3 Arg Precursors 45
- 1.4.3 Imidazole Group of His 45
- 1.4.4 Indole Group of Trp 48
- 1.4.5 ω -Amido Group of Asn and Gln 49
- 1.4.6 β -Thiol Group of Cys 50
- 1.4.6.1 Common Side-Reactions with S-Protected Cys Derivatives 51
- 1.4.6.1.1 Racemization 51
- 1.4.6.1.2 β -Elimination 51
- 1.4.6.1.3 Oxidation 51
- 1.4.6.2 Synthesis of Peptides Using Cystine as "Self-Protected" Cys 51
- 1.4.7 Thioether Group of Met 53
- 1.4.8 Hydroxy Group of Ser, Thr, and the Phenolic Group of Tyr 54
- 1.4.9 ω -Carboxy Group of Asp and Glu 55
- 1.4.9.1 Aspartimide Formation 55
- 1.5 Photocleavable Protections 57
- 1.6 Conclusions 58
- 1.7 Experimental Procedures 59
- 1.7.1 Protection Reactions 59
- 1.7.1.1 General Procedure for the Preparation of Tfa-Arg-OH 59

- 1.7.1.2 General Procedure for the Preparation of N^α -Phthaloyl Amino Acids using *N*-(Ethoxycarbonyl)phthalimide 59
- 1.7.1.3 General Procedure for the Preparation of N^α -Trt-Amino Acids 59
- 1.7.1.4 General Procedure for the Preparation of N^α -Ns-Amino Acids 60
- 1.7.1.5 General Procedure for the Preparation of N^α -Z-Amino Acids 61
- 1.7.1.5.1 Method A: Using Z-Cl 61
- 1.7.1.5.2 Method B: Using Z-OSu 62
- 1.7.1.6 General Procedures for the Preparation of N^α -Fmoc-Amino Acids 62
- 1.7.1.6.1 Method A: Using Fmoc-OSu 62
- 1.7.1.6.2 Method B: Using Fmoc-Cl and *N,O*-bis-TMS-Amino Acids 62
- 1.7.1.6.3 Method C: Using Fmoc-Cl in the Presence of Zinc Dust 63
- 1.7.1.6.4 Method D: Using Fmoc-N₃ 63
- 1.7.1.7 General Procedure for the Preparation of N^α -Nsc-Amino Acids 64
- 1.7.1.8 General Procedure for the Preparation of N^α -Bsmoc-Amino Acids 64
- 1.7.1.9 General Procedure for the Preparation of N^α -Aloc-Amino Acids 65
- 1.7.1.10 General Procedures for the Preparation of N^α -Boc-Amino Acids 65
- 1.7.1.10.1 Method A: Using (Boc)₂O 65
- 1.7.1.10.2 Method B: Using Boc-ON 65
- 1.7.1.10.3 Method C: Using Boc-N₃ 66
- 1.7.1.11 General Procedure for the Preparation of *N,N'*-di-Boc-Amino Acids 66
- 1.7.1.12 General Procedure for the Preparation of N^α -Bpoc-Amino Acids 67
- 1.7.1.13 General Procedures for the Preparation of Amino Acid Methyl Esters 68
- 1.7.1.13.1 Preparation of Amino Acid Methyl Ester Hydrochloride Salts 68
- 1.7.1.13.2 Isolation of Amino Acid Methyl Esters: Deprotonation of the Hydrochloride Salt Using Zinc Dust 69
- 1.7.1.13.3 Glutamic Acid α -Methyl, γ -*tert*-Butyl Diester Using Diazomethane 69
- 1.7.1.13.4 Z-Glu-OMe via Methanolysis of Cyclic Anhydride 69
- 1.7.1.14 General Procedure for the Preparation of Amino Acid Ethyl Esters 69
- 1.7.1.15 General Procedure for the Preparation of Amino Acid Benzyl Ester *p*-Toluenesulfonate Salts 70
- 1.7.1.15.1 Preparation of Amino Acid Benzyl Ester *p*-Toluenesulfonate Salts Under Microwave Irradiation 70
- 1.7.1.16 General Procedure for the Preparation of *tert*-Butyl Esters of N^α -Unprotected Amino Acids Using Isobutene 71
- 1.7.1.16.1 Preparation of Z-Phe-*Ot*Bu by the Silver Salt Method 71
- 1.7.1.17 General Procedure for Concomitant Protection and Activation of Amino Acids Using Pentafluorophenyl Carbonate 80

- 1.7.2 Deprotection Reactions 81
 - 1.7.2.1 Removal of the Phth Group by Hydrazinolysis 81
 - 1.7.2.2 Removal of the Nps Group 81
 - 1.7.2.3 Removal the Z-group 82
 - 1.7.2.3.1 Protocol A: Employing CH 82
 - 1.7.2.3.2 Protocol B: Employing Silylhydride 82
 - 1.7.2.3.3 Protocol C: Through CTH using 1,4-Cyclohexadieneas Hydrogen Donor 83
 - 1.7.2.4 Cleavage of the Fmoc Group 83
 - 1.7.2.4.1 Method A: Using TAEA [67] 83
 - 1.7.2.4.2 Method B: Using DEA: Simultaneous Removal of the Fmoc Group and 9-Fluorenylmethyl Ester 83
 - 1.7.2.5 Cleavage of the Boc Group 84
 - 1.7.2.5.1 Protocol A: Removal of the Boc group with TFA in the Presence of Scavengers 84
 - 1.7.2.5.2 Protocol B: Cleavage of Boc Group with TMS/Phenol 84
 - 1.7.2.6 Transprotection of N^α -Protecting Groups: Fmoc-Met-OH to Boc-Met-OH 84
 - 1.7.2.7 Selective Methyl Ester Hydrolysis in the Presence of the N^α -Fmoc Group 84
 - 1.7.2.8 Cleavage of *tert*-Butyl Ester Using $\text{BF}_3 \cdot \text{Et}_2\text{O}$ 84
 - 1.7.2.9 Selective Cleavage of Phenacyl Ester in the Presence of the N^α -Nosyl Group 85
 - 1.7.2.10 Removal of the Trt Group (Iodolysis) 85
 - 1.7.2.11 Deprotection of the Pbf Group from Z-Arg(Pbf)-OH 85
 - 1.7.2.12 Removal of the Phenoc Group through Photolysis 85
 - 1.7.2.13 Conversion of the DCHA Salt of N^α -Protected Amino Acids into Free Acids 85
- References 86

Part One Amino Acid-Based Peptidomimetics 99

- 2 Huisgen Cycloaddition in Peptidomimetic Chemistry 101**
Daniel Sejer Pedersen and Andrew David Abell
- 2.1 Introduction 101
- 2.2 Huisgen [2 + 3] Cycloaddition Between Azides and Acetylenes 102
- 2.3 Mechanistic Consideration for the Cu-Huisgen and Ru-Huisgen Cycloadditions 103
- 2.4 Building Blocks for the Synthesis of Triazole-Modified Peptidomimetics 106
- 2.5 Cyclic Triazole Peptidomimetics 109
- 2.6 Acyclic Triazole Peptidomimetics 113
- 2.7 Useful Experimental Procedures 121

2.7.1	Monitoring Huisgen Cycloadditions and Characterizing Triazoles	121
2.7.2	General Procedure for the Synthesis of 1,4-Triazoles Using Cu-Huisgen Cycloaddition	122
2.7.3	General Procedure for the Synthesis of 1,5-Triazoles Using Ru-Huisgen Cycloaddition	123
	References	124
3	Recent Advances in β-Strand Mimetics	129
	<i>Wendy A. Loughlin and David P. Fairlie</i>	
3.1	Introduction	129
3.1.1	β -Strands	129
3.1.2	β -Sheets	130
3.1.3	Differences in Strand/Sheet/Turn/Helix Recognition	130
3.1.4	Towards β -Strand Mimetics	131
3.2	Macrocyclic Peptidomimetics	133
3.3	Acyclic Compounds	135
3.4	Aliphatic and Aromatic Carbocycles	136
3.5	Ligands Containing One Ring with One Heteroatom (N)	137
3.6	Ligands Containing One or Multiple Rings with One Heteroatom (O, S)	138
3.7	Ligands Containing One Ring with Two Heteroatoms (N,N)	139
3.8	Ligands Containing One Ring with Two Heteroatoms (N,S) or Three Heteroatoms (N,N,S or N,N,N)	140
3.9	Ligands Containing Two Rings with One Heteroatom (N or O)	140
3.10	Ligands Containing Two Rings with Two or Three Heteroatoms (N,N or N,S or N,N,N)	141
3.11	Conclusions	142
	References	143
Part Two	Medicinal Chemistry of Amino Acids	149
4	Medicinal Chemistry of α-Amino Acids	151
	<i>Lennart Bunch and Povl Krosgaard-Larsen</i>	
4.1	Introduction	151
4.2	Glutamic Acid	151
4.3	Conformational Restriction	153
4.3.1	Synthesis – General Considerations	154
4.3.2	Case Study: Synthesis of DCAN	155
4.3.3	Case Study: Synthesis of LY354740	157
4.3.4	Case Study: Synthesis of ABHD-V and ABHD-VI	158
4.4	Bioisosterism	159
4.4.1	Case Study: Design and Synthesis of AMPA	160
4.4.2	Case Study: Design and Synthesis of Thioibotenic Acid	161
4.5	Structure–Activity Studies	162

4.5.1	Case Study: AMPA Analogs	162
4.5.2	Case Study: 4-Substituted Glu analogs	163
4.6	Conclusions	168
	References	169
5	Medicinal Chemistry of Alicyclic β-Amino Acids	175
	<i>Nils Griebenow</i>	
5.1	Introduction	175
5.2	Five-Membered Alicyclic β -Amino Acids	175
5.3	Six-Membered Alicyclic β -Amino Acids	183
	References	186
6	Medicinal Chemistry of α-Hydroxy-β-Amino Acids	189
	<i>Zyta Ziora, Mariusz Skwarczynski, and Yoshiaki Kiso</i>	
6.1	Introduction	189
6.2	α -Hydroxy- β -Amino Acids	189
6.2.1	α -Hydroxy- β -Amino Acids Occurring in Natural Products	189
6.2.2	Synthesis of α -Hydroxy- β -Amino Acids	191
6.2.2.1	Isoserine	191
6.2.2.2	Isothreonine	193
6.2.2.3	Phenylisoserine	197
6.2.2.4	Norstatines	197
6.2.2.5	3-Amino-2-Hydroxydecanoic Acid and its Analogs	204
6.2.2.6	Synthetic Demands	205
6.3	Antibacterial Agents	205
6.4	Inhibitors of Aminopeptidases	207
6.5	Aspartyl Proteases Inhibitors	211
6.5.1	Renin Inhibitors	212
6.5.2	HIV-1 Protease Inhibitors	216
6.5.3	HTLV-I Inhibitors	220
6.5.4	Plasmeprin II Inhibitors	222
6.5.5	BACE-1 Inhibitors	224
6.6	Paclitaxel and its Derivatives	228
	References	234
7	Peptide Drugs	247
	<i>Chiara Falciani, Alessandro Pini, and Luisa Bracci</i>	
7.1	Lights and Shades of Peptide and Protein Drugs	247
7.2	Peptide Drugs Available on the Market	249
7.2.1	Natriuretic Peptide (Nesiritide)	249
7.2.2	Oxytocin	249
7.2.3	Vasopressin	250
7.2.4	Desmopressin	251
7.2.5	Blood Coagulation Inhibitors	251
7.2.5.1	Bivalirudin	251

7.2.5.2	Integrilin (Eptifibatide)	251
7.2.6	Gonadotropin-Releasing Hormone Agonists and Antagonists	251
7.2.6.1	Gonadorelin	251
7.2.6.2	Lupron (Leuprolide)	252
7.2.6.3	Cetrorelix	253
7.2.6.4	Degarelix	253
7.2.7	Antihyperglycemics	254
7.2.7.1	Symlin (Pramlintide)	254
7.2.7.2	Exendin-4	254
7.2.7.3	Liraglutide	255
7.2.8	Icatibant	255
7.2.9	Sermorelin	256
7.2.10	Calcitonin	256
7.2.11	Parathyroid Hormone	256
7.2.12	Cyclosporine	257
7.2.13	Fuzeon	257
7.3	Approved Peptides in Oncology	258
7.3.1	Bortezomib	259
7.3.2	Actinomycin D	259
7.3.3	Marimastat	260
7.3.4	Octreotide	260
7.3.5	Vapreotide	261
7.3.6	Octreoscan	262
7.4	Antimicrobial peptides	263
7.4.1	Polymyxin	265
7.4.2	Daptomycin	266
7.4.3	Gramicidin S	267
7.5	Perspectives	267
7.5.1	Branched Peptides as Tumor-Targeting Agents	268
7.5.2	Branched Peptides as Antimicrobials	270
	References	271
8	Oral Bioavailability of Peptide and Peptidomimetic Drugs	277
	<i>Arik Dahan, Yasuhiro Tsume, Jing Sun, Jonathan M. Miller, and Gordon L. Amidon</i>	
8.1	Introduction	277
8.2	Fundamental Considerations of Intestinal Absorption	277
8.3	Barriers Limiting Oral Peptide/Peptidomimetic Drug Bioavailability	279
8.4	Strategies to Improve Oral Bioavailability of Peptide-Based Drugs	280
8.4.1	Chemical Modifications	280
8.4.1.1	Prodrug Approach	280
8.4.1.2	Structural Modifications	281

8.4.2	Formulation Technologies	284
8.4.2.1	Absorption Enhancers	284
8.4.2.2	Coadministration with Protease Inhibitors	285
8.4.2.3	Formulation Vehicles	285
8.4.2.4	Site-Specific Delivery	286
8.5	Conclusions	287
	References	287
9	Asymmetric Synthesis of β-Lactams via the Staudinger Reaction	293
	<i>Monika I. Konaklieva and Balbina J. Plotkin</i>	
9.1	Introduction	293
9.2	Staudinger Reaction	293
9.3	Influence of the Geometry of the Imine on Stereoselectivity in the Reaction	294
9.4	Influence of the Polarity of the Solvent on Stereoselectivity of the Reaction	296
9.5	Influence of the Isomerization of the Imine Prior to its Nucleophilic Attack onto the Ketene Stereoselectivity in the Reaction	296
9.6	Influence of the Order of Addition of the Reactants to the Reaction	297
9.7	Influence of Chiral Substituents on the Stereoselectivity of the Reaction	298
9.8	Asymmetric Induction from the Imine Component	298
9.9	Asymmetric Induction from the Ketene Component	305
9.10	Double Asymmetric Cycloinduction	308
9.11	Influence of Catalysts on the Stereoselectivity of the Reaction	309
9.11.1	General Procedure for β -Lactams 106 with Proton Sponge	312
9.11.2	General Procedure for the Tandem Nucleophile/Lewis Acid-Promoted Synthesis of β -Lactams 110	312
9.11.3	General Procedure for Catalytic Asymmetric Synthesis of <i>Trans</i> - β -Lactams 113	314
9.11.4	Example for Kinugasa Reaction with Cu (II) Catalyst	316
9.11.4.1	General Procedure for Catalytic Asymmetric Synthesis of β -Lactams 122	316
9.12	Conclusions	316
	References	317
10	Advances in N- and O-Glycopeptide Synthesis – A Tool to Study Glycosylation and Develop New Therapeutics	321
	<i>Ulrika Westerlind and Horst Kunz</i>	
10.1	Introduction	321
10.2	Synthesis of O-Glycopeptides	324
10.2.1	Synthesis of Mucin-Type Glycopeptides	325

10.2.1.1	Synthesis of Tumor-Associated Glycopeptides and Glycopeptide Vaccines	325
10.2.1.1.1	Synthesis of Tn, T, Sialyl-Tn, and Sialyl-T Glycosylated Amino Acid Building Blocks	325
10.2.1.1.2	Synthesis of Tn, T, Sialyl-Tn, and Sialyl-T Glycopeptides and Vaccines	329
10.2.1.2	Synthesis of Glycopeptide Recognition Domain of P-Selectin Glycoprotein Ligand-1	331
10.2.1.2.1	Synthesis of a Core 2 sLe ^x Amino Acid Building Block Including a sLe ^x Mimic	332
10.2.1.2.2	Synthesis of Unsulfated and Sulfated Core 2 sLe ^x and Core 2 sLe ^x Mimic PSGL-1 Glycopeptides	334
10.2.1.2.3	Chemoenzymatic Synthesis of Unsulfated and Sulfated sLe ^x PSGL-1 Glycopeptide	336
10.2.2	Synthesis of Other Types of O-Glycopeptides	339
10.2.2.1	Synthesis of Fmoc-GlcNAc-Ser/Thr Amino Acids	340
10.2.2.2	Synthesis of Estrogen Receptor Peptides for Conformational Analysis	340
10.3	Synthesis of N-Glycopeptides	342
10.3.1	Synthesis of RNase C Glycoprotein	343
10.3.2	Synthesis of Erythropoietin N-Glycopeptide Fragment 1–28	346
10.3.2.1	Synthesis of Biantennary Dodecasaccharide	346
10.3.2.2	Synthesis of N-Glycopeptide Fragment 1–28	348
10.3.3	Chemoenzymatic Synthesis of a HIV GP120 V3 Domain N-Glycopeptide	350
10.3.3.1	Synthesis of the Oxazoline Tetrasaccharide Donor	350
10.3.3.2	Synthesis of Fmoc-GlcNAc-Asn Amino Acid Building Block	351
10.3.3.3	Synthesis of V3 Cyclic GlcNAc Peptide and Endo A Coupling with Man ₃ GlcNAc Oxazoline Donor	352
	References	353
11	Recent Developments in Neoglycopeptide Synthesis	359
	<i>Margaret A. Brimble, Nicole Miller, and Geoffrey M. Williams</i>	
11.1	Introduction	359
11.2	Neoglycoside and Neoglycopeptide Synthesis	361
11.2.1	S-Glycosides	361
11.2.2	N-Glycosides	362
11.2.3	O-Glycosides	364
11.2.4	C-Glycosides	365
11.2.5	C=N Linkage	365
11.3	Protein Side-Chain Modifications	366
11.3.1	Modifications of Cysteine Side-Chains	366
11.3.2	Modifications of Lysine Side-Chains	369
11.3.3	Other Side-Chain Modifications	370
11.4	Cu(I)-Catalyzed Azide-Alkyne “Click” Cycloaddition	372

- 11.4.1 General Aspects of Cu(I)-Catalyzed Azide–Alkyne cycloaddition 372
- 11.4.2 Neoglycoside and Neoglycopeptide Synthesis via CuAAC 373
- 11.4.3 CuAAC and Neoglycoproteins 376
- 11.5 Cross-Metathesis 378
- 11.6 Application of Neoglycopeptides as Synthetic Vaccines 380
- 11.7 Enzymatic, Molecular, and Cell Biological Techniques 384
 - 11.7.1.1 Enzymatic Glycoprotein Synthesis 385
 - 11.7.2 Molecular and Cell Biological Techniques 385
- References 386

Part Three Amino Acids in Combinatorial Synthesis 393

- 12 **Combinatorial/Library Peptide Synthesis 395**
 - Michal Lebl*
 - 12.1 Introduction 395
 - 12.2 High-Throughput Synthesis of Peptides 396
 - 12.2.1 Parallel Peptide Synthesis 396
 - 12.2.2 Directed Sorting 400
 - 12.3 Synthesis of Peptide Arrays 402
 - 12.4 Peptide Libraries 406
 - 12.4.1 Synthesis of Peptide Mixtures 406
 - 12.4.2 Synthesis of Peptides on a Mixture of Particles 409
 - 12.4.2.1 Determination of the Structure of a Peptide on an Individual Bead 416
 - 12.4.3 Solution-Based Screening of OBOC Libraries 418
 - 12.5 Future of Peptide Libraries 421
 - 12.6 Synthetic Protocols 421
 - 12.6.1 Pin Synthesis 421
 - 12.6.2 SPOT Synthesis 422
 - 12.6.3 Synthesis in Tea-Bags 422
 - 12.6.4 Synthesis on Cotton 423
 - 12.6.4.1 Modification of the Cotton Carrier 423
 - 12.6.5 Split-and-Mix Synthesis of OBOC Noncleavable Libraries 424
 - 12.6.6 Preparation of Dual-Layer Beads 425
 - 12.6.7 Preparation of Library of Libraries 426
 - 12.6.8 Preparation of OBOC Libraries for Testing in Solution 426
 - 12.6.8.1 Synthesis of Multicleavable Linker 426
 - 12.6.8.2 Synthesis of the Library 428
 - 12.6.8.3 Quality Control of the Doubly Releasable Library 428
 - 12.6.8.4 Two-Stage Release Assay in 96-Well Microassay Plates 429
 - 12.6.9 Synthesis of the Positional Scanning Library 430

- 12.6.10 Synthesis of the Dual Defined Iterative Hexapeptide Library 430
- 12.6.11 Acylation Monitoring by Bromophenol Blue 431
References 432

- 13 Phage-Displayed Combinatorial Peptides 451**
Renhua Huang, Kritika Pershad, Malgorzata Kokoszka, and Brian K. Kay
- 13.1 Introduction 451
- 13.1.1 Types of Phage Vectors 452
- 13.1.2 Generation of Combinatorial Peptide Libraries 455
- 13.1.3 Identifying Peptide Ligands to Protein Targets 458
- 13.1.4 Mapping Protein–Protein Interactions 461
- 13.1.5 Identifying Peptide Ligands Binding to Cell Surfaces 463
- 13.1.6 Mapping Protease Specificity 464
- 13.1.7 Identifying Peptide Ligands to the Surfaces of Inert Materials 464
- 13.2 Conclusions 465
References 466

- 14 Designing New Proteins 473**
Michael I. Sadowski and James T. MacDonald
- 14.1 Introduction 473
- 14.1.1 Why Design New Proteins? 473
- 14.1.2 How New is “New?” 474
- 14.2 Protein Design Methods 475
- 14.2.1 Computational Design 476
- 14.2.1.1 Computational Enzyme Design 477
- 14.2.1.2 Results of Computational Design Experiments 478
- 14.2.2 Directed Evolution Methods 480
- 14.2.2.1 Randomization Strategies 480
- 14.2.2.2 Expression Systems and Assays 481
- 14.2.3 Design of Protein Interfaces 482
- 14.3 Protocol for Protein Design 484
- 14.4 Conclusions 486
References 487

- 15 Amino Acid-Based Dendrimers 491**
Zhengshuang Shi, Chunhui Zhou, Zhigang Liu, Filbert Totsingan, and Neville R. Kallenbach
- 15.1 Introduction. 491
- 15.2 Peptide Dendrimer Synthesis: Divergent and Convergent Approaches 491
- 15.2.1 Synthesis of the First Peptide Dendrimers: Polylysine Dendrimers 493
- 15.2.2 Glutamic/Aspartic Acid, Proline, and Arginine Dendrimers 494

15.2.3	Synthesis of MAPs	497
15.2.4	Synthesis of Peptide Dendrimers Grafted on PAMAM and other Peptide Dendrimers	500
15.3	Applications of Peptide Dendrimers	502
15.3.1	Initial Efforts on MAPs	502
15.3.2	Peptide Dendrimers as Antimicrobial Agents	502
15.3.3	Peptide Dendrimers as Protein/Enzyme Mimics	504
15.3.4	Peptide Dendrimers as Ion Sensors and MRI Contrast Agents	505
15.3.5	Peptide Dendrimers as DNA/RNA Delivery Vectors	507
15.3.6	Other Application of Peptide Dendrimers	512
15.4	Conclusions	513
	References	514

Index	519
--------------	-----